Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Gabapentin 300 mg hard capsules
Medicines register · Ireland

Gabapentin 300 mg hard capsules

Authorisation PA2315/164/004 · Accord Healthcare Ireland Ltd.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Accord Healthcare Ireland Ltd. (all products →)
Active substance
Gabapentin
Clinical trials
12 clinical trials →
Dosage form
Capsule, hard
Route of administration
Oral use
ATC code
N02BF01
First authorised
14/10/2016
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Gabapentin: supply and approvals

24 authorised products on the HPRA list contain Gabapentin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
12 supply notices, e.g. Gabapentin Aurobindo 800 mg Filmtabletten (3 Nov 2026 to 15 Mar 2027)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 10 years (since 14 October 2016). The HPRA list marks it as not marketed: it is licensed but the holder has not reported it as on sale.

Other medicines with Gabapentin in Ireland

23 other products on the HPRA list contain Gabapentin, from 7 licence holders; 11 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Gabapentin Rosemont 50 mg/ml Oral SolutionTaw Pharma (Ireland) LimitedNational authorisation (PA)Marketed
Gabapentin Thame 50 mg/ml oral solutionSyri Pharma Limited t/a Thame LaboratoriesNational authorisation (PA)Marketed
Gabin 100 mg capsules, hardAurobindo Pharma (Malta) LimitedNational authorisation (PA)Marketed
Gabin 300 mg capsules, hardAurobindo Pharma (Malta) LimitedNational authorisation (PA)Marketed
Gabin 400 mg capsules, hardAurobindo Pharma (Malta) LimitedNational authorisation (PA)Marketed
Neurontin 100 mg hard capsulesViatris Healthcare LimitedNational authorisation (PA)Marketed
Neurontin 300 mg hard capsulesViatris Healthcare LimitedNational authorisation (PA)Marketed
Neurontin 400 mg hard capsulesViatris Healthcare LimitedNational authorisation (PA)Marketed
Neurontin 600 mg film-coated tabletsViatris Healthcare LimitedNational authorisation (PA)Marketed
Neurontin 800 mg film-coated tabletsViatris Healthcare LimitedNational authorisation (PA)Marketed
Neurostil 300 mg hard capsulesTeva B.V.National authorisation (PA)Marketed
Gabapentin 100 mg hard capsulesAccord Healthcare Ireland Ltd.National authorisation (PA)Not marketed

All 24 products with Gabapentin →

The licence holder

Accord Healthcare Ireland Ltd. holds 238 products on the HPRA list, with 113 different active substances; 137 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.